A pharma firm based in Japan, with a US licensing office in New Jersey, is seeking to form partnerships and in-licensing relationships regarding early stage assets in its key indication areas. These partnerships are highly flexible, and may involve the pharma firm contributing personnel, sharing studies and research tools, or providing research expense funding.
The firm is interested in early-stage, first-in-class, orally active small molecule NCEs. The firm seeks assets in the following key areas: metabolic disease, infectious disease, cardiovascular disease, and autoimmune disease. Additionally, the firm is interested in kidney disease, pain and osteoperosis. As well as drugs, the pharma firm is interested in drug targets in these disease areas. The firm is open to forming partnerships regarding very early stage assets, at or prior to the lead optimization phase.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment